New Data Indicate Effectiveness Of Clarient’s Pulmotax(TM) Test For Lung Cancer
Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled “TLE3 expression is predictive of response to chemotherapy in …

Read more on Medical News Today